Multiple Sclerosis Discovery Forum

Inspiring Connections

Error message

No active batch.

Most Viewed

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Repurposing drugs for disease modification in multiple sclerosis
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Intas launches biosimilar version of Rituximab
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Architecture of human mTOR complex 1.

Pages